Biochips: A Global Strategic Business Report
San Jose, CA (PRWEB) March 09, 2012
Follow us on LinkedIn – Biochips industry continues to experience a shift away from research and development tools towards applied applications in areas such as clinical diagnostics, advanced sequencing, and drug discovery and development. The industry focus is currently centered on miniaturization as well as integration of biochip devices, reducing biochip cost, and enhancing their portability. Significant dimensions of the vast parallel studies afforded by biochips have created a holistic means of viewing biological systems. In addition to the combination of various sciences, space, time and expense are all key factors in the future development of biochips. At present, some chips assist scientists in identifying genes that are leading causes of a particular disease, while others facilitate in identifying the smallest changes among the same gene sequences or strands of DNA in persons with similar diseases. In addition, chips also shed light on the activities of proteins and antibodies that cause diseases. In future, identification of best markers for disease susceptibility and drug response is expected to boost the impact of biochips on the molecular diagnostics market.
As stated by the new market research report on Biochips, the US continues to remain the largest regional market, with its technological superiority. Segment-wise, DNA Chips constitute the largest market. Despite plummeting market share, the segment is likely to continue its dominance in the biochip products market through 2017. Global Protein Biochips market is set for robust growth driven by anticipated rise in demand from proteomics and gene expression profiling applications. Gene expression profiling is expected to continue as the leading application area for biochips, while pharmacogenomics is expected to register robust growth.
Major players in the marketplace include Affymetrix Inc., Agilent Technologies., Bio-Rad Laboratories Inc., Caliper Life Sciences Inc., Cepheid Inc., Fluidigm Corporation, GE Healthcare Ltd., Illumina, Inc., and Life Technologies Corporation, among others.
The research report titled "Biochips: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of trends, issues, strategic industry activities, and profiles of major companies worldwide. The report provides market estimates and projections (US$ Million) for the years 2009 through 2017 across global and regional markets for product segments including DNA Chips, Protein Chips, and Lab Chips. Geographic markets analyzed include the US, Canada, Japan, Europe, and Rest of World.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/